Cancer Aware · Patient & Family Guide

HPV Vaccination: A Complete Guide

HPV vaccination trains the immune system to prevent infection by covered HPV types. It works best before exposure and is a prevention measure, not treatment for an existing cancer.

Educational information for patients and families. This guide supports, but does not replace, individualized medical advice. It cannot diagnose, stage cancer or prescribe treatment.

All 25 chapters

Chapter 4 of 25

At a glance: HPV Vaccination: A Complete Guide
  1. Check age and vaccination record
  2. Choose the applicable national guidance
  3. Review immune status and pregnancy
  4. Complete valid doses; continue screening

What you will learn

Compare vaccine types and named schedules; understand catch-up vaccination; recognize situations requiring a tailored plan.

What the vaccines cover

Bivalent vaccines target HPV 16 and 18. Quadrivalent vaccines also cover wart-associated types 6 and 11. Nine-valent vaccines add five other cancer-associated types. Products and licensed ages differ between countries. The vaccine contains no live HPV and cannot cause HPV infection. A more extensive type range does not mean an already completed valid course must automatically be repeated.

Vaccination before sexual exposure gives the greatest benefit. A person already sexually active may still benefit because exposure to every covered type is unlikely. Routine HPV testing before vaccination is not generally necessary. A positive HPV result does not mean vaccination treats that infection; follow-up of the result remains a separate task.

WHO and national schedules are not identical

WHO's 2022 position supports one- or two-dose schedules for ages 9–20, with girls 9–14 the primary public-health target. For age 21 and older, WHO recommends two doses separated by about six months. People who are immunocompromised, including those living with HIV, should receive at least two and preferably three doses. These policy options do not automatically change every product label or national schedule.

The US CDC guidance describes routine vaccination at 11–12, starting as early as 9, and catch-up through 26. For selected adults 27–45, shared clinical decision-making considers future exposure and likely benefit; this is not routine vaccination for everyone. Starting before 15 generally uses two doses 6–12 months apart. Starting at 15 or older, or being immunocompromised in the relevant age group, uses three doses. Closely spaced or uncertain doses need review of actual dates.

India launched a national programme on 28 February 2026 offering a free, voluntary single dose of quadrivalent Gardasil-4 to girls aged 14, after consent. Programme eligibility is distinct from the broader clinical discussion about vaccination outside that age band. Ask the local public facility about access and a clinician about catch-up or immune suppression; do not assume the programme's single dose fits every special-risk situation.

Safety and practical preparation

Pain at the injection site, headache or a short-lived fever may occur. Fainting can happen around injections, particularly in adolescents, so observation while seated is useful. Serious allergic reactions are uncommon; tell the vaccinator about a severe reaction to a previous dose or component. Extensive safety monitoring has not established HPV vaccination as a cause of infertility.

Vaccination is usually deferred during pregnancy, with remaining doses considered afterward. An inadvertently administered dose is not by itself a reason to end a pregnancy; discuss it with the obstetric team. Breastfeeding is generally compatible. An interrupted series usually does not need to restart, but the provider must check valid ages and intervals under local guidance.

Protection and its limits

Protection has remained durable in long-term follow-up; routine boosters are not generally part of established schedules. The exact duration for an individual cannot be guaranteed. Vaccination does not cover every HPV type or rare HPV-independent cancer, and cannot reverse established precancer. Cervical screening therefore continues according to local guidance.

Misconception and common question

“Vaccination encourages sexual activity” is not a medical reason to withhold cancer prevention. Is it too late after one positive test? Not necessarily: discuss protection against types not yet acquired, while continuing the separate abnormal-result pathway.

Take-home messages

Use the actual vaccine record, age at first dose and named guideline. Distinguish WHO policy, national programme eligibility and individual clinical advice. Keep screening appointments after vaccination.

References and review status

Evidence/editorial check: 28 October 2026. AI-assisted preparation is separate from physician sign-off. Individual physician review is not recorded. Local approvals, resources and clinical guidance must be confirmed by the treating team.

Evidence scope and update policy